EE403 Cost-Effectiveness Analysis of Nivolumab Compared to Pembrolizumab in Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer Patients

The value for money associated with pembrolizumab versus nivolumab has not been evaluated head-to-head. objective of this analysis is to assess the cost-effectiveness in advanced or metastatic NSCLC patients from a third-party payer’s perspective. We developed three-state transition model [progression-free survival(PFS), post-progression survival, and death] based on phase III KEYNOTE-042 trial. Cycle length was 3 weeks 10-year time horizon. Transition probabilities were obtained following individual patient data (IPD) reconstruction survival curves trial parametric fitting. hazard ratios comparing network meta-analysis used as factors derived nivolumab. Utilities states real-world utility survey study. Direct medical costs publicly available sources. A 3% annual discount rate cost outcomes adjustment. incremental ratio (ICER) net monetary benefit (NMB)was estimated Sensitivity analyses conducted robustness. Patients accrued 0.97 QALY at $263,480 while accruing 0.96 $259,835, resulting an ICER $358,127/QALY. NMB be $-2,118 willingness pay(WTP) threshold $150,000. One-way sensitivity shown that most sensitive acquisition both medications PFS ranging $-1,402,502 $2,118,756 per QALY. results show cost-effective compared nivolumab, WTP $150,000 patients.